New Times,
New Thinking.

  1. Business
  2. Economics
11 October 2011

98 of FTSE 100 companies use tax havens

New research by ActionAid uncovers 8,492 overseas subsidiary companies.

By Alice Gribbin

Every single company on the London Stock Exchange, bar two, uses round-the-world tax havens, often costing developing countries far more than they receive annually in aid, a report by ActionAid has revealed.

Ninety-eight per cent of the country’s biggest businesses are afforded widespread financial secrecy and tax levies by holding jurisdictions in 8,492 companies outside of the UK. This makes up a quarter of the FTSE 100’s total 34,000 subsidiaries.

The four big banks (Barclays, HSBC, Lloyds and RBS) alone have 1,649 firms located in tax havens.

ActionAid’s research is based on previously undisclosed data. FTSE companies are required by law to disclosed information on their subsidiary businesses, however, ActionAid’s analysis found that over half “were not complying with this legal obligation”. The child sponsorship chairty submitted complaints to Companies House, thereby forcing Stock Exchange businesses to re-file their annual returns.

Select and enter your email address Your weekly guide to the best writing on ideas, politics, books and culture every Saturday. The best way to sign up for The Saturday Read is via saturdayread.substack.com The New Statesman's quick and essential guide to the news and politics of the day. The best way to sign up for Morning Call is via morningcall.substack.com
Visit our privacy Policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications.
THANK YOU

A graphic map of the FTSE 100 tax havens can be found on the ActionAid website, here.

Content from our partners
Unlocking investment in UK life sciences through manufacturing
Data defines a new era for fundraising
A prescription for success: improving the UK's access to new medicines